Vascular biomarkers in COVID-19
Classification . | Biomarker . | Clinical association in COVID-19 ARDS . | Comparison with non–COVID-19 ARDS . |
---|---|---|---|
Endothelial inflammation | Angpt-2 | Death,52-54,93,97 ICU admission,16 disease severity54,71,92,94,147 | Higher in COVID-19,53 no difference147 |
ICAM1 | COVID vs healthy,148 death,53,93 disease severity92 | Higher in COVID-1953,149 | |
VCAM1 | COVID vs healthy,148 death,150 disease severity92 | Higher in COVID-1953 | |
E-selectin | COVID vs healthy,54,148 death,54,93 disease severity74,92 | Higher in COVID-1953 | |
P-selectin | COVID vs healthy,148 death,54,91 disease severity54,92 | Higher in non–COVID-19 ARDS53 | |
VEGF-A | Disease severity85,97,98 | ||
VEGFR-1 | Disease severity,54,151 death151 | Higher in COIVD152 | |
Thrombosis | PAI-1 | Disease severity15,72,86,96,150 | No difference153,154 |
Thrombomodulin | Death,15 disease severity54,71,92,94 | No difference153,155 | |
vWF | COVID vs healthy,148 death,92,93 disease severity54,71,73,88,92,94,156 | No difference87,154 | |
TFPI | Disease severity54,71,88 | ||
tPA | Disease severity73,74 | ||
Glycocalyx | Syndecan-1 | COVID-19 vs healthy,86,87 disease severity85,88 | Higher in COVID-19,87 higher in non-COVID90 |
Hyaluronic acid | COVID-19 vs healthy,87 disease severity85,90 | Higher in COVID,87 higher in non-COVID90 | |
Heparan sulfate | Disease severity89,90 | Higher in non-COVID90 |
Classification . | Biomarker . | Clinical association in COVID-19 ARDS . | Comparison with non–COVID-19 ARDS . |
---|---|---|---|
Endothelial inflammation | Angpt-2 | Death,52-54,93,97 ICU admission,16 disease severity54,71,92,94,147 | Higher in COVID-19,53 no difference147 |
ICAM1 | COVID vs healthy,148 death,53,93 disease severity92 | Higher in COVID-1953,149 | |
VCAM1 | COVID vs healthy,148 death,150 disease severity92 | Higher in COVID-1953 | |
E-selectin | COVID vs healthy,54,148 death,54,93 disease severity74,92 | Higher in COVID-1953 | |
P-selectin | COVID vs healthy,148 death,54,91 disease severity54,92 | Higher in non–COVID-19 ARDS53 | |
VEGF-A | Disease severity85,97,98 | ||
VEGFR-1 | Disease severity,54,151 death151 | Higher in COIVD152 | |
Thrombosis | PAI-1 | Disease severity15,72,86,96,150 | No difference153,154 |
Thrombomodulin | Death,15 disease severity54,71,92,94 | No difference153,155 | |
vWF | COVID vs healthy,148 death,92,93 disease severity54,71,73,88,92,94,156 | No difference87,154 | |
TFPI | Disease severity54,71,88 | ||
tPA | Disease severity73,74 | ||
Glycocalyx | Syndecan-1 | COVID-19 vs healthy,86,87 disease severity85,88 | Higher in COVID-19,87 higher in non-COVID90 |
Hyaluronic acid | COVID-19 vs healthy,87 disease severity85,90 | Higher in COVID,87 higher in non-COVID90 | |
Heparan sulfate | Disease severity89,90 | Higher in non-COVID90 |